July 28, 2021 -- Thermo Fisher Scientific reported a significant revenue increase during the second quarter of 2021.
For the period (end-July 3), revenue grew 34% to $9.27 billion, compared with $6.92 billion in the second quarter of 2020.
During this period, the company launched a new clinical and commercial cell therapy manufacturing facility at the University of California, San Francisco, as well as research collaboration to support the scale-up of studies and research in metabolomics. Also, Thermo Fisher brought additional capacity online to support vaccine and therapy production globally and expanded the production of laboratory plastics in North America and Europe.
After the quarter closed, the company opened a new plasmid DNA facility in California. It was opened to meet the demand for DNA-based therapies and mRNA-based vaccines, Thermo Fisher said.